Boston Scientific Corp.
BSX
Market Cap$156.32B
Close$
Earnings Call Q2 2025
July 23, 2025 - AI Summary
Strong Q2 Performance: Boston Scientific reported a Q2 2025 total operational sales growth of 22%, surpassing expectations significantly. Organic sales grew 17%, exceeding the guidance range of 13% to 15%. Adjusted EPS reached $0.75, a 23% increase YOY, exceeding the guidance of $0.71 to $0.73.
Outlook for Growth: The company raised its full-year organic growth guidance from 12%-14% to 14%-15%. For Q3, organic growth is projected to be in the range of 12%-14%. Adjusted EPS for the full year is forecasted to be between $2.95 and $2.99, entailing an 18%-19% growth from 2024.
Sales Performance by Segment: The Cardiovascular segment grew significantly, with sales increasing by 28%. Key contributors included WATCHMAN (up 28%) and FARAPULSE, which gained traction in multiple regions, particularly Japan and China. Additionally, the Urology segment demonstrated a solid 28% growth operationally, although organic growth was more modest at 6%.
Exclusive for Stockcircle Pro members
Sign up
$75.25
29.9% downside
Current Fair Value
29.9% downsideOvervalued by 29.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $156.32 Billion |
|---|---|
| Enterprise Value | $167.20 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.26 |
| Beta | 0.66 |
| Outstanding Shares | 1,478,500,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 62.34 |
|---|---|
| PEG | 42.7 |
| Price to Sales | 8.94 |
| Price to Book Ratio | 7.15 |
| Enterprise Value to Revenue | 9.04 |
| Enterprise Value to EBIT | 59.82 |
| Enterprise Value to Net Income | 66 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Boston Scientific Corp.
2,020 employees
CEO: Michael Mahoney